On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46. The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion. The increase was primarily due to growth contributions from several of our acquired products, key in-line products, and recent commercial launches, which more than offset both an expected decline in Comirnaty. Also Read: Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study. Excluding contributions from Comirnaty and Paxlovid, revenues reached $12.8 billion, increased 14% operationally. In the second ...